Compare CALX & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALX | CNTA |
|---|---|---|
| Founded | 1999 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 6.1B |
| IPO Year | 2009 | 2021 |
| Metric | CALX | CNTA |
|---|---|---|
| Price | $43.38 | $39.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $66.50 | $43.17 |
| AVG Volume (30 Days) | 1.1M | ★ 3.0M |
| Earning Date | 04-21-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.78 | 29.13 |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $510,367,000.00 | $15,000,000.00 |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $13.75 | N/A |
| P/E Ratio | $258.94 | ★ N/A |
| Revenue Growth | ★ 11.24 | N/A |
| 52 Week Low | $40.75 | $10.95 |
| 52 Week High | $71.22 | $40.26 |
| Indicator | CALX | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 37.32 | 73.10 |
| Support Level | N/A | $39.16 |
| Resistance Level | $56.30 | $40.26 |
| Average True Range (ATR) | 2.04 | 0.19 |
| MACD | -0.54 | -0.48 |
| Stochastic Oscillator | 21.50 | 59.18 |
Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Europe, Americas excluding U.S., and Rest of World.
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.